Montelukast sodium 4 mg Oral Tablet
RxNorm 391880

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 391880 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: montelukast sodium 4 mg Oral Tablet.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
Montelukast 4 mg Oral Tablet
Primary clinical definition
AUI:1633901
View
PSN
Montelukast sodium 4 mg Oral Tablet
AUI:6364331
View
PT
Montelukast sodium 4 mg oral tablet
AUI:9252035
View
FN
Product containing precisely montelukast sodium 4 mg/1 each conventional release oral tablet (clinical drug)
AUI:10315101
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCD

Semantic Clinical Drug (SCD):
Montelukast 4 mg Oral Tablet
(Atom ID: 1633901)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
montelukast 4 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
391880
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
1633901
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
391880
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{330865} 115713
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{330865} 88249
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{330865} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXTERM FORM
Tab
The RxTerm dose form name for this drug
PSN

Prescribable Name (PSN):
Montelukast sodium 4 mg Oral Tablet
(Atom ID: 6364331)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
montelukast sodium 4 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
391880
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6364331
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
391880
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
PT

Designated preferred name (PT):
Montelukast sodium 4 mg oral tablet
(Atom ID: 9252035)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Montelukast sodium 4 mg oral tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
391880
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
9252035
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PT
Designated preferred name ()
Source Code
376830007
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.
FN

Full form of descriptor (FN):
Product containing precisely montelukast sodium 4 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 10315101)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Product containing precisely montelukast sodium 4 milligram/1 each conventional release oral tablet (clinical drug)
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
391880
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10315101
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
FN
Full form of descriptor ()
Source Code
376830007
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
US Edition of SNOMED CT (SNOMEDCT_US)
The official name and abbreviation for the vocabulary source.
Source Version
2026_01_31
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
National Library Of Medicine, NLM is a Charter Member of SNOMED International on behalf of the U.S., National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, 1-888-FIND-NLM (1-888-346-3656), , https://support.nlm.nih.gov/support/create-case/,
Source licensing contact information.

Patient Education

Montelukast


Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older. Montelukast is also used to treat the symptoms of seasonal (occurs only at certain times of the year), allergic rhinitis (a condition associated with sneezing and stuffy, runny or itchy nose) in adults and children 2 years of age and older, and perennial (occurs all year round) allergic rhinitis in adults and children 6 months of age and older. Montelukast should be used to treat seasonal or perennial allergic rhinitis only in adults and children who cannot be treated with other medications. Montelukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of substances in the body that cause the symptoms of asthma and allergic rhinitis.
[Learn More]


* Please review the disclaimer below.